NCT05131893View on ClinicalTrials.gov

Neoadjuvant Treatment of Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

December 31, 2031

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen

endocrine therapy

DRUG

Goserelin

endocrine therapy

DRUG

Letrozole 2.5Mg Tab

endocrine therapy

DRUG

Epirubicin

chemotherapy

DRUG

cyclophosphamide

chemotherapy

DRUG

Docetaxel

chemotherapy

DRUG

paclitaxel

chemotherapy

DRUG

trastuzumab

biological treatment

DRUG

pertuzumab

biological treatment

DRUG

Capecitabine

chemotherapy

Trial Locations (1)

1122

National Institute of Oncolgy, Budapest

All Listed Sponsors
lead

National Institute of Oncology, Hungary

OTHER

NCT05131893 - Neoadjuvant Treatment of Breast Cancer | Biotech Hunter | Biotech Hunter